Abstract: A method for producing a solid electrolyte powder includes preparing a mixed solution by adding a poor solvent to a good solvent solution that contains a good solvent and a solid electrolyte that contains an alkali metal element and/or an alkaline earth metal element, Sn and S; removing at least some of the good solvent from the mixed solution to precipitate solid electrolyte particles; and drying the solid electrolyte particles to obtain a solid electrolyte powder. The ratio of the volume of the poor solvent relative to the volume of the good solvent (volume of poor solvent/volume of good solvent) is 5 or more.

Abstract: A method for producing an LGPS-type solid electrolyte mixing Li3PS4 crystals having an average grain size (D50) of 0.1 to 5 ?m and crystals that are formed of Li, Sn and S to produce a precursor, while having an average grain size (D50) of 0.1 to 5 ?m; and subjecting the precursor to heat treatment at 300 to 700° C.

Abstract: Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor is represented by general formula (1) (excluding clotrimazole) and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent.

Abstract: Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor is represented by general formula (1) (excluding clotrimazole) and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent.

Abstract: Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor is represented by general formula (1) (excluding clotrimazole) and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent.

Abstract: Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor comprises a compound represented by general formula (1) (excluding clotrimazole), and/or a pharmacologically acceptable salt thereof.

Abstract: Biphenyl derivatives represented by the following formula (1): wherein R1 represents a C5-7 alkyl group, R2 represents a substituted or unsubstituted aromatic hydrocarbon, or cycloalkyl group, R3 represents a tetrazolyl group, —NHCOCF3, —NHSO2CF3 or —SO2NHCONHR4 in which R4 represents a substituted or unsubstituted aromatic hydrocarbon group, and Z represents a single bond, a C1-4 alkylene group or —SO2NH—, and salts thereof; and ACAT inhibitors and medicines containing them as active ingredients. The compounds according to the present invention possess excellent ACAT inhibitory activities, and are useful as preventives and/or therapeutics for diseases cased by the enhancement of ACAT activity, for example, hypercholesterolemia, atherosclerosis and the like.

Abstract: Biphenyl derivatives represented by the following formula (1): 1

Abstract: The invention relates to a therapeutic and preventive medicament for respiratory diseases, comprising, as an active ingredient, a compound represented by the general formula (1): wherein R1 represents a linear, branched or cyclic alkyl group having 1 to 10 carbon atoms; and R2 represents a hydrogen or halogen atom, a substituted alkyl group, an amino group which may be substituted, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, or an alkylcarbamoyl group, or a salt thereof. This compound has excellent tracheobronchodilative effect and inhibitory effect on airway constriction.

Abstract: The invention relates to compounds represented by the following general formula (1): ##STR1## wherein R.sup.1 represents an alkyl group, R.sup.2 represents an amino group, alkyl group or the like, and R.sup.3 represents a nitro group, amino group, heterocyclic group, alkylsulfonylamino group or the like, or salts thereof, medicines comprising such a compound, a preparation process of the compounds, and intermediates useful for preparation thereof. The compounds (1) are useful for the prevention and treatment of a respiratory disease.

Abstract: The invention relates to compounds represented by the following general formula (1): ##STR1## wherein R.sup.1 represents an alkyl group, R.sup.2 represents an amino group, alkyl group or the like, and R.sup.3 represents a nitro group, amino group, heterocyclic group, alkylsulfonylamino group or the like, or salts thereof, medicines comprising such a compound, a preparation process of the compounds, and intermediates useful for preparation thereof. The compounds (1) are useful for the prevention and treatment of a respiratory disease.